Nile Therapeutics, Inc. Reports 2008 Third Quarter Financi...(ard-looking statements. We maynot actual...),Health

Date:11/13/2008

ard-looking statements. We may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that we make are described in greater detail in the reports we file with Securities and Exchange Commission, including the "Risk Factors" section of our Annual Report on Form 10-KSB, which was filed with the Securities and Exchange Commission on March 27, 2008. Nile is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Nile Therapeutics, Inc.

(A Development Stage Company)

Condensed Statements of Operations

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

-------------------- --------------------

2008 2007 2008 2007

Grant income $ - $ 101,400 $ - $ 101,400

Operating expenses

Research and

development 2,556,900 2,175,558 7,423,738 3,596,835

General and

adminis-

trative 818,761 2,562,891 2,977,263 3,284,387

Total

operating

expenses 3,375,661 4,738,449 10,401,001 6,881,222

Loss from

operations (3,375,661) (4,
'/>"/>

SOURCE Nile Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Cell Therapeutics, Inc. (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
2. Cell Therapeutics, Inc. (CTI) Oppenheimer & Co. Healthcare Conference Presentation to be Webcast
3. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
5. Cell Therapeutics, Inc. Announces $12 Million Equity Line of Credit
6. Stiefel Laboratories, Inc. Announces Expiration of Hart-Scott-Rodino Waiting Period Relating to its Proposal to Acquire Barrier Therapeutics, Inc.
7. Zevalin Revenues Lead Cell Therapeutics, Inc.s First Quarter 2008 Financial Results
8. Juvaris BioTherapeutics, Inc. Announces the Appointment of Grant E. Pickering as Chief Executive Officer
9. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and 2007 Fourth Quarter and Year End Financial Results
10. Oracle Healthcare Acquisition Corp. and Precision Therapeutics, Inc. Mutually Terminate Merger Agreement; Oracle Healthcare Acquisition Corp. Cancels Special Meeting
11. Cell Therapeutics, Inc. Announces Issuance of $51.7 Million of New 2012 Convertible Senior Notes